Search

Your search keyword '"Evofosfamide"' showing total 129 results

Search Constraints

Start Over You searched for: Descriptor "Evofosfamide" Remove constraint Descriptor: "Evofosfamide"
129 results on '"Evofosfamide"'

Search Results

101. Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma

102. Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects

103. Successes, failures, and future prospects of prodrugs and their clinical impact.

104. 18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.

105. Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021

106. PCM-13THE HYPOXIA-ACTIVATED PRODRUG EVOFOSFAMIDE (TH-302) IS EFFICACIOUS IN PEDIATRIC HIGH GRADE GLIOMA CELL LINES AS A MONOTHERAPY AND IN COMBINATION WITH CHEMOTHERAPIES

107. MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)

108. Evofosfamide combined with gemcitabine/nab-paclitaxel in patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma (PAC): Results of a phase I trial

109. Randomized, double-blind, placebo-controlled trial of evofosfamide (Evo) and pemetrexed (Pem) in advanced non-squamous non-small cell lung cancer (n-s NSCLC)

110. Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study

111. A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial

112. Abstract PR003: Hypoxia is an essential driver of immune suppression in the tumor microenvironment

113. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302

114. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

115. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

116. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs

117. Abstract B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors

118. Abstract A163: The combined treatment modality of a hypoxia-activated prodrug (Evofosfamide) with ionizing radiation

119. Metabolism of Hypoxia-Activated Prodrug Evofosfamide in Hypoxic and Normoxic Conditions and Its Potential to Enhance the Therapeutic Efficacy of Single-Dose Radiation Therapy in Pancreatic Cancer

120. 2312 Japanese phase I trial of hypoxia-activated prodrug evofosfamide (TH-302) as monotherapy in patients with solid tumors or in combination with gemcitabine in patients with advanced pancreatic cancer

121. Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM)

122. A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma

123. Randomized, Double-Blind, Placebo-Controlled Trial of Evofosfamide (TH-302) in Combination with Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer

124. Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma.

125. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.

126. Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.

127. Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.

128. [Untitled]

129. [Untitled]

Catalog

Books, media, physical & digital resources